COPENHAGEN, Denmark, Sept. 29, 2026 -- Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announced the successful close of...
Pappas Capital targets $200M at next generation of Asian innovation
Pappas Capital's Asia Innovation Ventures is a $200M fund targeting next generation technologies in Asia. The fund was more than two years in the making and is a way to tap into innovation in China, Hong Kong and Singapore.
